Notice of AGM

EKF Diagnostics Holdings plc (AIM: EKF), announces that its Annual General Meeting will be held on Thursday 2 June 2016 at 11am at the offices of Harwood Capital LLP, 6 Stratton Street, Mayfair, London W1J 8LD, and not on 19 May 2016 as previously stated in the Company’s Final Results announcement.

Back to Listing Previous Next

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

Director/PDMR Shareholding

EKF Diagnostics Holdings plc (AIM: EKF) announces that on 24 May 2019, the Company was notified by Adam Reynolds, Non-executive Director, that he has today sold 400,000 ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares").

Acquisition of further interest in Renalytix AI plc

EKF Diagnostics Holdings notes the announcement by Renalytix AI plc, that on 26 April 2019 EKF Diagnostics plc acquired 100,074 ordinary RenalytixAI shares of £0.0025 each.

Posting of Annual Report & Accounts and Notice of AGM

EKF Diagnostics confirms that the Annual Report and Accounts for the year ended 31 December 2018 and the Notice of the Annual General Meeting contained therein are available.

Final results

EKF Diagnostics Holdings plc announces its final results for the year ended 31 December 2018.

Notice of Results

EKF announces that it will release its preliminary results for the year ended 31 December 2018 on Wednesday 13 March 2019.